The short answer
Panax ginseng may affect glucose control. Review the product before combining it with ertugliflozin; the exact added low-blood-sugar risk has not been measured.
What this answer covers
Asian ginseng root extracts, with berry and other Panax species distinguished.
- Supplement or preparation
- Panax ginseng
- Medication ingredient
- ertugliflozin
What the human evidence shows
One small trial of a vinegar-extracted root product improved HbA1c at the lowest tested dose. A berry study had no overall glucose benefit, and acute Asian-ginseng findings were also inconsistent. These were not this medicine’s combination trials.
Why your treatment context matters
Ertugliflozin particularly increases low-blood-sugar risk when combined with insulin or insulin-releasing medicines. It should not be assumed to behave like those medicines by itself. The prescriber should consider the full regimen, meals and prior low readings before deciding whether additional monitoring is useful.
Check the supplement preparation
Check species, root versus berry, extract and daily amount. American ginseng or a different extract cannot be treated as an equivalent exposure.
Keep the prescribed medicine plan
Keep the prescribed ertugliflozin plan and tell the clinician about reduced intake, illness, vomiting or diarrhea. Do not change diabetes doses or fluid and salt advice to compensate for a supplement without review.
Watch for low blood sugar
Follow your existing glucose-monitoring and low-blood-sugar treatment plan. New sweating, shakiness, hunger or confusion warrants a glucose check when possible. Severe confusion, a seizure or inability to swallow safely needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional glucose-monitoring concern follows from supplement glucose effects and the exact medicine context. This is not direct evidence of increased hypoglycemia or altered drug absorption.
- Exact scope
- Asian ginseng root extracts, with berry and other Panax species distinguished. with Exact ertugliflozin L-pyroglutamic acid single-ingredient oral tablets. Exact RxNorm IN1992672; STEGLATRO uses ertugliflozin L-pyroglutamic acid equivalent to the active ingredient. Metformin and sitagliptin combinations excluded.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact pair human interaction trial identified. Preparation-specific positive and null results do not establish a universal effect, safe dose, spacing rule or drug concentration change.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed ertugliflozin.
Glucosuria, volume depletion, ketoacidosis precautions; hypoglycemia risk increases with insulin or insulin secretagogues. No routine sodium replacement instruction.
How this applies: Exact RxNorm IN1992672; STEGLATRO uses ertugliflozin L-pyroglutamic acid equivalent to the active ingredient. Metformin and sitagliptin combinations excluded.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: Original human clinical study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 72 drug-naive adults with type 2 diabetes.
The lowest tested dose showed an HbA1c benefit; no severe adverse events reported.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Small groups and no concomitant diabetes medicine. The extract is not equivalent to berry products or every commercial ginseng.
Source 3: Original human clinical study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 72 people randomized, 63 completing a 12-week trial.
No overall glycemic benefit in the full population; a higher-fasting-glucose subgroup showed some improvement.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Subgroup findings do not overturn the overall null result. Berry differs from root and is not a ertugliflozin co-use study.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two small healthy-volunteer acute dose studies.
Overall incremental glucose and insulin measures were unchanged; one pooled two-hour glucose comparison was higher.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Acute studies without ertugliflozin; extract composition and dose varied.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: b8bd2d278ded8413
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.